Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vivus: into single digits -- Ignore unavailable to you. Want to Upgrade?

To: Colby who wrote (402)	4/28/1998 2:48:00 PM
From: BDR	Read Replies (1) \| Respond to of 1016

<One out of 10 men in the clinical trials developed blinding headaches that grew more severe at higher doses. >> Incidence and perhaps severity of side effects increase with the dose. In the clinical trials Pfizer tested up to 800mg., currently recommend a limit of 100mg. The company describes the headaches as "mild" and among those who dropped out of the study 2.5% dropped out because of side effects (all kinds) which is about the same number that dropped out of the placebo group because of side effects. They may have massaged the numbers. Who knows. <<It seems to me, this headache combined with the other affects and inability of Viagra to mix with other drugs such as nitroglycerine leaves a lot of the ED market available for the likes of VVUS. >> I have written perhaps thiry scrips for Viagra, or given out samples now that I have them, to new patients. I have refused one patient because he was on nitroglycerin. I don't know how you translate that into meaningful numbers for the market share. Nitro users may know they can't take it and aren't coming in to ask for it. They may be lying about it in order to get VIagra. They may actually forget that they take nitro once or twice a month when asked.